信迪利单抗联合化疗对肺鳞癌疗效及T细胞计数的影响

Effect of Sintilimab Combined with Chemotherapy on Efficacy and T Cell Count in Lung Squamous Cell Carcinoma

目的探讨信迪利单抗治疗肺鳞癌的效果及其对T细胞计数的影响。方法收集92例肺鳞癌患者,将研究对象分为病例组(42例)和对照组(50例)。病例组给予信迪利单抗免疫治疗联合紫杉醇+顺铂化疗,对照组给予紫杉醇+顺铂化疗,治疗2周期后比较病例组和对照组在临床疗效的差异,治疗前后T细胞CD3^(+)、CD4^(+)、CD8^(+)计数变化情况、以及药物副作用的发生状态。结果病例组疗效与对照组疗效相比显著改善(P<0.05)。病例组CD4^(+)T细胞计数水平较对照组明显提高(P<0.05)。两组在副作用发生率相比无临床意义(P>0.05)。结论信迪利单抗联合化学治疗可显著提高肺鳞癌患者治疗疗效,亦可以提升CD4^(+)T细胞的计数水平。

Objective To investigate the effect of sintilimab in the treatment of lung squamous cell carcinoma and its effect on T cell count.Methods A total of 92 patients with lung squamous cell carcinoma were collected and divided into a case group(42 cases)and a control group(50 cases).The case group was given sintilimab immunotherapy combined with paclitaxel+cisplatin chemotherapy,while the control group was given paclitaxel+cisplatin chemotherapy.After 2 cycles of treatment,the differences in clinical efficacy between the case group and the control group,the changes in T cell CD3^(+),CD4^(+),CD8^(+)counts before and after treatment,and the occurrence of drug side effects were compared.Results The curative effect of the case group was significantly improved compared with that of the control group(P<0.05).The CD4^(+)T cell count in the case group was significantly higher than that in the control group(P<0.05).There was no clinical significance in the incidence of side effects between the two groups(P>0.05).Conclusion Sintilimab combined with chemotherapy can significantly improve the treatment efficacy of patients with lung squamous cell carcinoma,and can also increase the count level of CD4^(+)T cells.